SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Merck
MRK 108.23-0.9%Jan 13 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: LTK007 who wrote (435)12/4/1997 8:51:00 PM
From: Bruce Russell  Read Replies (3) of 1580
 
The MK869 is very big news. It gives the prospect of back filling and overcoming the patent expirations of Vasotec, Pepcid and Mevacor in 1999, 2000 and 2001 (about 3 billion in revenues). If MK-869 does what Prozac and Buspar do without the cotten mouth, it will be a super block buster, and should hit market in 2001.

Merck's already going to do well with Propesia, Singulaire, Maxalt, Cox-2, all of them could be Billion sellers, who knows how well Propecia will sell, if all the young balding computer nerds buy it.

Regards,

Bruce
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News